Esculin
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Esculin: From an Unspecified Original Indication to Amenorrhea
One-Sentence Summary
Esculin is a coumarin glucoside found in three products authorised in Canada, but the data compiled for this report do not specify an original approved indication. The TxGNN model predicts it may be effective for amenorrhea, but there are currently 0 clinical trials and 0 publications supporting this direction. This is a computational prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the available data |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 0.9921 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 3 of 3) |
| Number of DINs | 3 (marketed: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Esculin is a coumarin glucoside (a derivative of esculetin) with reported antioxidant and anti-inflammatory properties. No original indication is listed in the data compiled for this report.
Nothing in the available data connects these properties to the hormonal or hypothalamic-pituitary-ovarian pathways involved in amenorrhea. The only support for this prediction is the high TxGNN score (0.9921), which comes from a network-based computation. Any mechanistic link would be speculation and would need independent validation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02247882 | PROCTOL SUPPOSITORIES | Not stated | Not stated |
| 02247322 | PROCTOL OINTMENT | Not stated | Not stated |
| 02226383 | TEVA-PROCTOSONE | Not stated | Not stated |
All three products are valid authorisations. Their names suggest rectal or anorectal use, which is not obviously aligned with amenorrhea. Route compatibility has not yet been assessed.
Safety Considerations
Please refer to the package insert for safety information. No drug-interaction records were found in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. There are no clinical trials, no publications, no mechanism data and no documented original indication. The marketed products also appear to be rectal or topical formulations, which have no evident link to amenorrhea.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Approved indication text for the three Canadian products
- A plausible biological link between esculin and the pathways involved in amenorrhea, supported by preclinical or literature evidence
- An assessment of route and formulation compatibility with the proposed use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.